Skip Navigation LinksHome > June 2014 - Volume 9 - Issue 6 > Radiation Pneumonitis in Patients with Non–Small-Cell Lung C...
Journal of Thoracic Oncology:
doi: 10.1097/JTO.0000000000000126
Brief Reports

Radiation Pneumonitis in Patients with Non–Small-Cell Lung Cancer Treated with Erlotinib Concurrent with Thoracic Radiotherapy

Zhuang, Hongqing MD, PHD*; Yuan, Zhiyong MD, PHD*; Chang, Joe Y. MD, PHD; Wang, Jun MD*; Pang, Qingsong MD*; Zhao, Lujun MD, PHD*; Wang, Ping MD, PHD*

Collapse Box

Abstract

Introduction:

The aim of this study was to investigate the incidence of radiation pneumonitis in patients with non–small-cell lung cancer treated with concurrent thoracic radiotherapy and erlotinib.

Methods:

Patients with inoperable stages IIIA to IV non–small-cell lung cancer who were treated with concurrent thoracic radiotherapy and erlotinib were analyzed. The incidence of radiation pneumonitis was evaluated using the Common Toxicity Criteria (CTC) 3.0 Grading System. The development of grade 2 or higher radiation pneumonitis was the study end point.

Results:

Among the 24 patients analyzed, there were nine developed radiation pneumonitis of grade 2 or higher (37.5%), including four cases of grade 2 radiation pneumonitis (16.7%), two of grade 3 radiation pneumonitis (8.3%), and three of grade 5 radiation pneumonitis (12.5%). Three patients developed fatal pneumonia and died of bilateral lung radiation pneumonitis.

Conclusions:

Radiation pneumonitis should be considered in patients treated with concurrent thoracic radiotherapy and erlotinib.

Copyright © 2014 by the International Association for the Study of Lung Cancer

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.